PARIS, France & Mumbai, Maharashtra, India:
Dr. Nagendra Boopathy Senguttuvan presented ground-breaking findings from the GENESIS-II trial at the prestigious EuroPCR 2024 conference, providing light on the Hydra transcatheter heart valve (THV)’s exceptional performance in treating severe aortic stenosis. The trial, led by Sahajanand Medical Technologies (SMT), demonstrated the Hydra THV’s remarkable safety and effectiveness, with a paltry 2.5% cardiovascular death rate and an amazing 95% device success rate at 30 days post-intervention.
The GENESIS-II research, which included 19 medical locations across India, enrolled 40 high-risk patients diagnosed with severe aortic stenosis. The results showed not only low death rates, but also few complications and significant clinical improvements, validating the Hydra THV’s ability to improve patient outcomes. Dr. Anmol Sonawane, a famous specialist participated in the study, emphasized the Hydra THV’s novel features, particularly its active release mechanism, which improves deployment precision and therapeutic results for patients with severe aortic stenosis. Dr. Krishna Sudheer, SMT’s Chief Medical Officer, underlined the study’s success, highlighting the Hydra THV’s safety and performance. The GENESIS-II study results strengthen the Hydra THV’s position as a premier transcatheter aortic valve implantation (TAVI) device for treating severe aortic stenosis, adding to earlier evidence and confirming its efficacy in enhancing patient care.
In summary, the GENESIS-II research marks a significant advancement in transcatheter aortic valve technology, highlighting the Hydra THV’s remarkable safety, efficacy, and potential to revolutionize the therapeutic landscape for patients with severe aortic stenosis.
